Prime Medicine Inc (PRME) concluded trading on Wednesday at a closing price of $3.07, with 6.67 million shares of worth about $20.48 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 5.86% during that period and on July 02, 2025 the price saw a gain of about 12.45%. Currently the company’s common shares owned by public are about 131.16M shares, out of which, 51.66M shares are available for trading.
Stock saw a price change of 26.86% in past 5 days and over the past one month there was a price change of 157.98%. Year-to-date (YTD), PRME shares are showing a performance of -40.27% which increased to 5.14% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.11 but also hit the highest price of $6.75 during that period. The average intraday trading volume for Prime Medicine Inc shares is 2.43 million. The stock is currently trading 55.82% above its 20-day simple moving average (SMA20), while that difference is up 87.13% for SMA50 and it goes to 17.18% higher than SMA200.
Prime Medicine Inc (NASDAQ: PRME) currently have 131.16M outstanding shares and institutions hold larger chunk of about 28.96% of that.
The stock has a current market capitalization of $403.07M and its 3Y-monthly beta is at 2.28. It has posted earnings per share of -$1.66 in the same period. It has Quick Ratio of 4.78 while making debt-to-equity ratio of 1.13. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PRME, volatility over the week remained 17.97% while standing at 14.51% over the month.
Stock’s fiscal year EPS is expected to rise by 23.33% while it is estimated to increase by 20.83% in next year. EPS is likely to grow at an annualized rate of 18.30% for next 5-years, compared to annual growth of -124.13% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on May 27, 2025 offering a Neutral rating for the stock and assigned a target price of $1.50 to it. On May 20, 2025, H.C. Wainwright Downgrade their recommendations, while on December 10, 2024, JMP Securities Initiated their ratings for the stock with a price target of $10. Stock get a Buy rating from H.C. Wainwright on May 20, 2024.
